BRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company's development of a competing medicine.
The commission said the pharmaceutical firm “misused the patent system to artificially extend patent protection” for its blockbuster MS drug Copaxone, whose active ingredient is glatiramer acetate.
To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in Europe containing glatiramer acetate, the commission said in a statement.
Teva “spread information contradicted by health authorities’ findings, seeking to sow doubt on the safety, efficacy and therapeutic equivalence of the rival product,” the EU Commission said. It said Teva officials targeted doctors and groups involved in drug pricing and reimbursement, “with the target of slowing down or blocking its competitor's entry” into several countries.
In a statement, Teva said it disagreed with the EU Commission's decision, which it described as “based on legal theories ... that are extreme, untested, and factually unsupported.” It said it intends to appeal the decision and that it has supported the MS community since 1996.
The EU Commission said Teva's actions may have prevented significant savings by countries across Europe, with other versions of the drug possibly 80% cheaper than Copaxone. Teva will have to pay a fine of 462.6 million euros ($502 million) and refrain from similar practices in the future, it said.
Last year, Teva was ordered to pay $225 million to settle price fixing charges in the U.S. related to sales of a cholesterol-lowering drug. The U.S. Justice Department said the agreement also required Teva to divest its business making and selling the drug pravastatin, a generic version of the brand-name medicine Pravachol.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
